医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

WE Brands in Motion Health Study: Corporate Reputation Is Leading Factor in Prescribing Decisions

2023年02月28日 PM11:00
このエントリーをはてなブックマークに追加


 

NEW YORK & LONDON & SINGAPORE

Today, WE Communications (WE) released its latest Brands in Motion global report, “Healthy Reputation: More Than Medicine.” The data reveals that, outside a medication’s functional characteristics, healthcare professionals ranked corporate reputation as the foremost influencing factor when it comes to making prescribing decisions.

Across the globe, healthcare professionals want the peace of mind that they are recommending treatments from companies they respect — and building that respect goes well beyond producing high-quality drug therapies. Two-thirds of those surveyed said they are reluctant to prescribe medications from companies with a less than stellar reputation.

“The positive sentiment biotech and pharmaceutical brands earned during COVID-19 has waned; the industry is now at an important crossroads to maintain that confidence,” said WE’s EVP Health Innovation & Growth, Gemma Hudson. “Our research indicates that healthcare professionals want pharma to go beyond medicine and address the entire healthcare experience, from education and support right through to tackling societal and environmental issues.”

This year’s study uncovers three main themes:

POSITIVE CORPORATE REPUTATION IMPACTS THE BOTTOM LINE

WE Brands in Motion global health study found that when treatments have similar profiles, the maker’s overall corporate reputation is the No. 1 factor influencing healthcare professionals’ decisions to prescribe or recommend a drug. On a scale of 1 to 10, with 10 being most important, corporate reputation ranked at nearly 8 by healthcare professionals. The second biggest influence is the company’s reputation as a leader in a particular disease area.

To address these findings, biotech and pharma companies must prioritize development of corporate reputation programs that include thought leadership, medical education for healthcare professionals and advocacy for patients.

“For years, healthcare communicators have asked to what degree corporate reputation informs prescribing decisions of healthcare professionals. Now we know. It is incredibly important,” said President, WE Global Health, Stephanie Marchesi. “It impacts the bottom line.”

DELIVERING MORE THAN MEDICINE IS HEALTHCARE PROFESSIONALS’ EXPECTATION

The new data finds that healthcare professionals hold biotech and pharma brands to a particularly high standard, more than companies in other sectors, to go beyond their mission to provide medicines that treat and prevent diseases. In other words, they expect biotech and pharmaceutical companies to deliver “more than medicine.”

Nine out of 10 healthcare professionals surveyed say biotech and pharmaceutical companies should support improving patient health outcomes in ways beyond high-quality drug therapies. Seventy-three percent believe these companies should add value to society beyond providing their goods and services; for instance, offering medical education and patient support, as well as driving sustainability initiatives.

“The pressure on brands to deliver beyond their traditional remit has grown significantly in recent years — and no industry is feeling it more than healthcare,” said Hudson. “Developing new treatments will always be at the heart of the pharma industry, but creating great medicines is only the start. Health brands can and should contribute in ways that enhance the entire health ecosystem in which they operate and then also go beyond it, using their influence to tackle social and environmental challenges.”

HEALTHCARE PROFESSIONALS QUESTION IF PATIENT CENTRICITY IS REAL

Patient centricity is the top characteristic that healthcare professionals want brands to embody, with being innovative and progressive taking the second and third spots, respectively. However, only 45% of respondents believe that biotech and pharmaceutical companies are delivering this to a “great” or “large” extent.

When it comes to being patient-centric, healthcare professionals place offering patient support programs, improving understanding of complex health information, and demonstrating understanding of the lived patient experience — both physical and emotional — as the top three things they expect from industry.

“Some might say that these things are table stakes for any pharma or biotech company. But these companies need to ask themselves, and the healthcare professionals they work with, if their efforts to prioritize patients are sufficient or if they should be doing more,” said Marchesi. “In the end what matters to healthcare professionals is proof that a company is doing the right things versus the promise they will do so.”

ABOUT BRANDS IN MOTION

Partnering with Sapio Research, WE surveyed more than 1,000 healthcare professionals in Australia, China, Germany, India, the United Kingdom and the United States to understand their perspectives on the biotech and pharmaceutical industry.

“Healthy Reputation: More Than Medicine” is part of WE Communications’ Brands in Motion global research. Now in its seventh year, Brands in Motion has surveyed more than 100,000 consumers and business decision-makers about how perceptions shift over time.

ABOUT WE

WE is one of the largest independent communications and integrated marketing agencies in the world. We’re all about people — both our clients and employees — and we believe in the power of communications to move audiences to positive action. Female-founded, female-led, and fiercely independent, WE has spent more than three decades helping world-class brands tell technology-led transformation stories that shift perceptions and change behavior.

Our global reach includes offices in 21 cities, partner networks that expand our footprint and client capabilities, and a team of more than 1,500 media and content strategists, creatives and data scientists across our technology, health, and consumer sectors. Our work with global brands like Microsoft, Intel, McDonald’s, and Volvo has been recognized by Cannes Lions, PRovoke SABRE Awards and PRWeek Awards, just to name a few.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005038/en/

CONTACT

Kara Kraft, WE, (503) 443-7143, karak@we-worldwide.com

同じカテゴリーの記事 

  • Bridge Biotherapeutics to Present Tuesday at the BIO International Convention
  • Signing of Exclusive Distributorship Agreement With EVERZOM
  • PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi® (ropeginterferon alfa-2b-njft) in Latin America
  • AOP Health:已完成的研究加强了用于真性红细胞增多症的ropeginterferon alpha 2b (BESREMi®)的临床开发计划
  • AOPヘルス:研究結果が真性多血症を対象としたロペグインターフェロンアルファ-2b(ベスレミ)の臨床開発プログラムを後押し